By Professor Andrew David Carr

Journal articles

Kovacic JC; Martin A; Carey DL; Wand HC; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr AD, 2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143

Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Ganning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray JM; Gerlach W; Sun L; Penny R; Symonds GP; Carr AD; Cooper DA, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients', Journal of Gene Medicine, 7, pp. 552 - 564

Grinspoon SK; Carr AD, 2005, 'Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults', New England Journal of Medicine, 352, pp. 48 - 62

Mallon PW; Sedwell R; Unemori P; Kelleher AD; Cooper DA; Carr AD, 2005, 'Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy', Antiviral Therapy, 10, pp. M101 - M108

Lim H; Sedwell R; Duarte NL; Cooper DA; Kelleher AD; Carr AD; Mallon PW, 2005, 'Nucleoside reverse transcriptase inhibitor effects on adipocyte mitochondrial DNA quantity and quality in vitro', Antiviral Therapy, 10, pp. L41 - L42

Visnegarwala F; Raghavan S; Mullin C; Bartsch G; Wang J; Kotler DP; Gibert C; Shlay J; Grunfeld C; Carr AD; El-Sadr W, 2005, 'Sex differences in the associations of HIV disease characteristics and body composition in anti retroviral-naive persons', American Journal of Clinical Nutrition, 82, pp. 850 - 856

Winston A; McAllister J; Amin J; Cooper DA; Carr AD, 2005, 'The use of a triple nucleoside-nucleotide-regimen for occupational HIV post-exposure prophylaxis', HIV Medicine, 6, pp. 191 - 197

Calmy A; Pascual F; Ford N; Kulwichit W; Carr A, 2004, 'First-line and second-line antiretroviral therapy [7] (multiple letters)', Lancet, 364, pp. 329 - 330

Ledergerber B; Lundgren JD; Sarah Walker A; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; John Gill M; Castelli F; Phillips AN; Rooney P; Taylor S; Couldwell D; Austin D; Block M; Clemons J; Finlayson R; Petoumenos K; Quan D; Smith D; O'Connor C; Gorton C; Allen D; Mulhall B; Mutimer K; Keeffe N; Cooper D; Carr A; Miller J; Pell C; Ellis D; Baker D; Kidd J; McFarlane R; Liang MT; Brown K; Huffam S; Savage J; Morgan S; Knibbs P; Sowden D; Walker A; Orth D; Lister G; Chuah J; Fankhauser W; Dickson B; Bradford D; Wilson C; Ree H; Magon H; Anderson J; Moore R; Russell D; McGovern G; McNair R; Bal J; Fairley K; Roth N; Eu B; Strecker S; Wood H; Mijch A; Hoy J; Pierce A; McCormack C; Watson K; Medland N; Daye J; Mallal S; French M; Skett J; Maxwel D; Cain A; Montroni M; Scalise G; Costantini A; Giacometti A; Tirelli U; Nasti G; Pastore G; Ladisa N; Perulli ML; Suter F; Arici C; Maggiolo F; Chiodo F; Gritti FM; Colangeli V; Fiorini C; Guerra L; Carosi G, 2004, 'Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes', Lancet, 364, pp. 51 - 62, http://dx.doi.org/10.1016/S0140-6736(04)16589-6

Cavalcanti RB; Raboud J; Kain KC; Walmsley S; Carr A; Wand H, 2004, 'Rosiglitazone for HIV-1 lipoatrophy [3] (multiple letters)', Lancet, 363, pp. 1828 - 1829, http://dx.doi.org/10.1016/S0140-6736(04)16318-6

Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98

Ellis K; Grund B; Visnegarwala F; Mullin C; Miller C; Chesson C; El-Sadr W; Carr AD, 2004, 'Abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) measurements in HIV+ adults: influences of measurement site', Antiviral Therapy, 9, pp. L34 - L35

Carr AD, 2004, 'Antiretroviral therapy for previously untreated HIV-1-infected adults:2NN, or just one?', Lancet, 363, pp. 1248 - 1250

Hoy JF; Gahan M; Carr AD; Smith DE; Lewin S; Wesselingh S; Cooper DA, 2004, 'Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir', Journal of Infectious Diseases, 190, pp. 688 - 692

Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56

Carr AD, 2004, 'First-line and second-line antiretroviral therapy - Author`s reply', Lancet, 364, pp. 330 - 330

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11

Carr AD; Workman C; Carey DL; Rogers GJ; Martin A; Baker DA; Wand HC; Law MG; Samaras K; Emery S; Cooper DA, 2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy:randomised, double-blind, placebo-controlled trial', Lancet, 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5

Mallon PW; Sedwell R; Unemori P; Merlin K; McGinley C; Ammaranond P; Peperias M; Rafferty M; Williams KM; Samaras K; Morey AL; Chisholm DJ; Kelleher AD; Cooper DA; Carr AD, 2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', Antiviral Therapy, 9, pp. L56 - L57

Law MG; Cheng AJ; Cooper DA; Carr AD, 2004, 'Objective evaluation of HIV lipodystrophy case definition in a randomized 96 week clinical trial', Antiviral Therapy, 9, pp. L8 - L9

Martin A; Smith DE; Carr AD; Hoy JF; Chuah J; Mallal SA; Law MG; Clements MS; Cooper DA, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://thomasland.metapress.com/content/0gu76x27mmhe5ale/

Martin A; Smith DE; Carr AD; Ringland C; Amin J; Emery S; Hoy JF; Workman C; Doong N; Freund J; Cooper DA, 2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870

Carey DL; Workman C; Rogers GJ; Baker DA; Martin A; Wand HC; Emery S; Cooper DA; Carr AD, 2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, 9, pp. L46 - L46

Carr AD; Wand HC, 2004, 'Rosiglitazone for HIV-1 Lipoatrophy', The Lancet, 363, pp. 1829 - 1829, http://dx.doi.org/10.1016/S0140-6736(04)16319-8

Carr AD; Wand HC, 2004, 'Rosiglitazone for HIV-1 lipoatrophy - Reply', Lancet, 363, pp. 1829 - 1829

Vanhems P; Voirin N; Philippe P; Hirschel B; Brassard J; Carr AD; Cooper DA; Perrin L; Allard R, 2004, 'The incubation period of acute retroviral syndrome as a multistepprocess - A parametric survival analysis', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 37, pp. 1529 - 1533

Bisson G; Gross R; Miller V; Weller I; Walker A; Arlett P; Carr A; Evans S; Graham D; Justice A; Kreft-Jais C; Lundgren JD; Munk B; Murray J; Pirmohamed M; Pizzuti D; Szarfman A; Writing group , 2003, 'Monitoring of long-term toxicities of HIV treatments: an international perspective.', AIDS, 17, pp. 2407 - 2417, http://dx.doi.org/10.1097/00002030-200311210-00002

Friis-Møller N; Sabin CA; Weber R; d'Arminio Monforte A; El-Sadr WM; Reiss P; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Law MG; Kirk O; Phillips AN; Lundgren JD; Bartsch G; Dabis F; Houyez F; Loeliger E; Tressler R; Weller I; Sjøl A; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Meester R; Lavignolle V; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; Hammer S; Neaton J; de Wolf F; van der Ven E; Zaheri S; Van Valkengoed I; Bronsveld W; Weigel H; Brinkman K; Frissen P; ten Veen J; Hillebrand M; van Dam P; Schieveld S; Mulder J; van Gorp E; Meenhorst P; van Eeden A; Danner S; Claessen F; Perenboom R; Eeftinck Schattenkerk JK; Godfried M; Lange J; Lowe S; van der Meer J; Nellen F; Pogany K; van der Poll T; Prins J; Ruys T; van der Valk M; Wit F; Richter C; van Leusen R; Vriesendorp R; Jeurissen F; Kauffmann R; Koger E; Bravenboer B; ten Napel C; Sprenger HG; Law G; ten Kate RW; Leemhuis M; Kroon F; Schippers E; Schrey G; van der Geest S; Verbon A; Koopmans P; Keuter M; Telgt D; van der Ven A; van der Ende M; Gyssens I; de Marie S; Juttmann J; van der Heul C; Schneider M; Borleffs J; Hoepelman I; Jaspers C; Matute A; Schurink C, 2003, 'Combination Antiretroviral Therapy and the Risk of Myocardial Infarction: The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group', New England Journal of Medicine, 349, pp. 1993 - 2003, http://dx.doi.org/10.1056/NEJMoa030218

Carr A, 2003, 'Cardiovascular risk factors in HIV-infected patients', Journal of Acquired Immune Deficiency Syndromes, 34, http://dx.doi.org/10.1097/00126334-200309011-00011

Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA, 2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004

Vanhems P; Voirin N; Hirschel B; Cooper DA; Vizzard J; Carr A; Perrin L, 2003, 'Incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS', Journal of Acquired Immune Deficiency Syndromes, 32, pp. 542 - 544, http://dx.doi.org/10.1097/00126334-200304150-00012

Carr A, 2003, 'Lactic acidemia in infection with human immunodeficiency virus', Clinical Infectious Diseases, 36, http://dx.doi.org/10.1086/367565

Smith DE; Hudson J; Martin A; Freund J; Griffiths MR; Kalnins S; Law M; Carr A; Cooper DA; Group and Investigators FTPD, 2003, 'Centralized Assessment of Dual-Energy X-ray Absorptiometry (DEXA) in Multicenter Studies of HIV-Associated Lipodystrophy', HIV Research & Clinical Practice, 4, pp. 45 - 49, http://dx.doi.org/10.1310/hct.2003.4.1.006

Carr AD; Emery S; Law MG; Puls R; Lundgren JD; Powderly W, 2003, 'An objective case definition of lipodystrophy in HIV-infected adults: a case-control study', Lancet, 361, pp. 726 - 735

Carr AD; Law MG, 2003, 'An objective lipodystrophy severity grading scale using the lipodystrophy case definition score', Journal of Acquired Immune Deficiency Syndrome, 33, pp. 571 - 576

Raghavan S; Mullin C; Bartsch G; Wang J; Kotler DP; Shlay J; Gibert C; Grunfeld C; Carr AD, 2003, 'Association between HIV disease characteristics with total and regional body composition levels in antiretroviral-naive men and women', Antiviral Therapy, 8, pp. L66 - L66

Carr AD, 2003, 'Cardiovascular risk in HIV infection', Journal of Acquir Immun Defic Syndrome, 34, pp. 73 - 78

Smith DE; Hudson J; Martin A; Freund J; Griffiths MR; Kalnins S; Law MG; Carr AD; Cooper DA, 2003, 'Centralised assessment of dual-energy x-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy', HIV Clinical Trials, 4, pp. 45 - 49

Clegg AO; Williamson P; Biti RA; Cooper DA; Emery S; Carr AD; Stewart GJ, 2003, 'Chemokine receptor genotype and response to interleukin-2 therapy in HIB-1-infected individuals', Clinical Immunology, 106, pp. 36 - 40

Amin J; Moore A; Carr AD; French MA; Law MG; Emery S; Cooper DA, 2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261

Carr AD, 2003, 'Enfuvirtide, an HIV-1 fusion inhibitor', New England Journal of Medicine, 349, pp. 1770 - 1771

Cunningham PH; Marriott D; Harris C; Hancock S; Carr AD; Cooper DA; Harris C, 2003, 'False negative HIV-1 proviral DNA polymerase chain reaction in a patient with primary infection acquired in Thailand', Journal of Clinical Virology, 26, pp. 163 - 169

Smith DE; Kaufmann GR; Kahn JO; Hecht FM; Grey PA; Zaunders J; Cunningham PH; Carr AD; Duncombe CJ; Quan D; Petersen A; Cooper DA, 2003, 'Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine and nelfinavir before complete HIV type 1 seroconversion', AIDS Research and Human Retroviruses, 19, pp. 189 - 199

Ioannidis JP; Trikalinos TA; Law MG; Carr AD, 2003, 'HIV lipodystrophy case definition using artificial neural network modelling.', Antiviral Therapy, 8, pp. 435 - 441

Miller J; Carr AD; Emery S; Law MG; Mallal SS; Baker D; Smith DG; Kaldor JM; Cooper DA, 2003, 'HIV lipodystrophy: prevalence, severity and correlates of risk in Australia', HIV Medicine, 4, pp. 293 - 301

Carr AD, 2003, 'HIV Lipodystrophy: risk factors, pathogenesis, diagnosis and management', AIDS, 17, pp. 141 - 148

Lincoln DW; Petoumenos K; Dore GJ, 2003, 'HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy', HIV Medicine, 4, pp. 241 - 249

Carr AD, 2003, 'Lactic acidemia in HIV infection', Clinical Infectious Diseases, 36, pp. 96 - 100

Mallon PW; Cooper DA; Carr AD, 2003, 'Longterm treatment complications. I', AIDS, pp. 127 - 144

Mallon PW; Cooper DA; Carr AD, 2003, 'Metabolic complications of antiretroviral therapy', AIDS and Other Manifestations of HIV Infection, pp. 853 - 868

Back to profile page